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Abstract
Introduction: Catecholamines are the most used vasopressors in vasodilatory shock. However, the development of
adrenergic hyposensitivity and the subsequent loss of catecholamine pressor activity necessitate the search for
other options. Our aim was to evaluate the effects of vasopressin and its analog terlipressin compared with
catecholamine infusion alone in vasodilatory shock.
Methods: A systematic review and meta-analysis of publications between 1966 and 2011 was performed. The
Medline and CENTRAL databases were searched for studies on vasopressin and terlipressin in critically ill patients.
The meta-analysis was limited to randomized controlled trials evaluating the use of vasopressin and/or terlipressin
compared with catecholamine in adult patients with vasodilatory shock. The assessed outcomes were: overall
survival, changes in the hemodynamic and biochemical variables, a decrease of catecholamine requirements, and
adverse events.
Results: Nine trials covering 998 participants were included. A meta-analysis using a fixed-effect model showed a
reduction in norepinephrine requirement among patients receiving terlipressin or vasopressin infusion compared
with control (standardized mean difference, -1.58 (95% confidence interval, -1.73 to -1.44); P < 0.0001). Overall,
vasopressin and terlipressin, as compared with norepinephrine, reduced mortality (relative risk (RR), 0.87 (0.77 to
0.99); P = 0.04). Vasopressin compared with norepinephrine decreased mortality in adult patients (RR, 0.87 (0.76 to
1.00); P = 0.05) and in patients with septic shock (42.5% vs. 49.2%, respectively; RR, 0.87 (0.75 to 1.00); P = 0.05;
number needed to treat, 1 to 15). There was no difference in adverse events between the vasopressin and control
groups (RR, 0.98 (0.65 to 1.47); P = 0.92).
Conclusions: Vasopressin use in vasodilatory shock is safe, associated with reduced mortality, and facilitates
weaning of catecholamines. In patients with septic shock, use of vasopressin compared with norepinephrine may
also decrease mortality.
Introduction
The mortality rate of patients with shock remains high
[1]. Vasodilatory shock is characterized by low arterial
blood pressure due to a significantly decreased systemic
vascular resistance. The most frequent causes of this
type of shock are sepsis and post-cardiovascular surgery
requiring cardiopulmonary bypass. However, massive
vasodilatation can result from shock of any origin [1].
Aggressive volume resuscitation is the mainstay of
initial shock management, followed by vasoactive infu-
sions when fluids do not restore adequate arterial pres-
sure and tissue perfusion [2]. Currently, catecholamines
are the preferred vasopressor but the development of
adrenergic hyposensitivity with the loss of pressor
responsiveness makes finding other options necessary
[3]. Additionally, catecholamines - especially dopamine
and epinephrine - have significant adverse effects, such as
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decreased cardiac output and oxygen delivery, arrhyth-
mia, and organ ischemia, especially at high doses.
Catecholamines may even increase mortality rates [3].
Vasopressin is a neurohypophyseal hormone with
diverse actions mediated by tissue-specific receptors.
Low-dose vasopressin and its analog terlipressin have
emerged as promising therapies in vasodilatory shock
for several reasons. The rationale for using vasopressin
and its analogs is the development of relative vasopres-
sin deficiency in patients with vasodilatory shock and
the observation that exogenously administered vasopres-
sin restores vascular tone, increases responsiveness to
infused catecholamines and raises blood pressure,
thereby reducing the need for catecholamine use [4].
Observational and randomized controlled studies invol-
ving the use of vasopressin infusion in patients with vaso-
dilatory shock have produced conflicting results. Our aim
was to summarize these studies using a systematic review
of the literature and a meta-analysis of randomized con-
trolled trials focused on vasopressin and its analog terli-
pressin in adult patients with vasodilatory shock. We also
evaluated vasopressin and terlipressin in studies of septic
shock only.
Materials and methods
Search methods for identification of studies
Studies were identified using the Medline (1966 to 2011)
and CENTRAL (1800 to 2011) databases using a sensitive
search strategy combining medical subject headings and
keywords (see Additional file 1 for details). Abstracts
from recent major conferences (American Thoracic
Society, European Society of Intensive Care Medicine,
and Society of Critical Care Medicine) were searched for
additional relevant studies. All of the review articles and
cross-referenced studies from the retrieved articles were
screened for pertinent information.
Selection of studies
This meta-analysis was limited to studies that dealt with
the role of vasopressin and/or terlipressin compared with
catecholamine infusion in the treatment of vasodilatory
shock in adult critically ill patients. Vasodilatory shock
was defined as hypotension due to peripheral vasodilata-
tion as result of failure of the vascular smooth muscle to
constrict [2]. We included trials that satisfied the follow-
ing inclusion criteria: randomized controlled trials com-
paring adult critically ill patients who had vasodilatory
shock receiving treatment with vasopressin or terlipressin
compared with patients not receiving such treatment;
survival, biochemical and hemodynamic data; and
patients in the studies receiving vasoactive infusion in the
control arm and vasopressin plus vasoactive infusion in
the experimental arm. Studies were excluded if survival
outcome or biochemical and/or hemodynamic data were
not provided, if pediatric patients were analyzed, or if
they included patients without vasodilatory shock. When
we found duplicate reports of the same study in prelimin-
ary abstracts and articles, we analyzed data from the most
complete dataset.
Data extraction
Data were independently extracted from each report by
three authors, using a data-recording form developed for
this purpose. After extraction, data were reviewed and
compared by ASN. Disagreements between the two
extractors were solved by consensus among the investiga-
tors. Whenever needed, additional information concern-
ing a specific study was obtained by directly questioning
the principal investigator.
Definition of endpoints
The primary endpoint was overall survival. The survival
time was defined as the time from randomization until
death from any cause, or was censored on the date of the
last follow-up assessment. Secondary endpoints included:
change in hemodynamic variables; change in biochemical
variables; decrease of catecholamine requirements; and
assessment of adverse events.
Statistical analysis
The effects of vasopressin and terlipressin on vasodilatory
shock outcomes and the adverse effects of these drugs
were examined. We extracted data regarding the study
design, patient characteristics, treatment duration, medi-
cation, dosage, mean change for hemodynamic and bio-
chemical variables, overall survival, and decreased
catecholamine requirement. Changes in hemodynamic
and biochemical variables were expressed as a percentage
and were defined as the final value (after follow-up)
minus the baseline value divided by the baseline value.
The decreased catecholamine requirement was defined as
any sustained decrease in catecholamine infusion over
the study follow-up period. Norepinephrine and dopa-
mine infusions were reported as micrograms per minute,
vasopressin infusion was reported as units per minute,
and terlipressin infusion was reported as micrograms
per hour. The conversion of weight-based variables
(μ/kg/minute) to time-based variables (μg/minute or
μg/hour) was made by multiplying the value by the mean
weight, either provided by the author or estimated as
70 kg. The conversion of bolus administration (mg) to
continuous administration (μg/hour) was made by divid-
ing the total daily dose by 24 and multiplying it by a con-
version factor (mg to μg). All of the time variables were
described as hours, and the other variables are described
in the text.
For the survival analysis and for the proportion of
patients who experienced adverse events, a pooled
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estimate of the relative risks (RRs) of the individual studies
was computed using a fixed-effect model, according to
Mantel and Haenszel, and these results graphically repre-
sented using forest plot graphs. For continuous variables,
the standardized mean difference, which consists of the
difference in means divided by the standard deviation, was
used. The homogeneity assumption was checked by a chi-
squared test with the degrees of freedom equal to the
number of analyzed studies minus one. A sensitivity analy-
sis was performed by recalculating the pooled RR esti-
mates for different study subgroups based on the relevant
clinical features. This analysis serves to show whether the
overall result would be affected by a change in the meta-
analysis selection criteria [5]. An estimate of the potential
publication bias was carried out by plotting the single-
study RR on a log scale against the respective standard
error (funnel plot). For multiple comparisons, we used the
Bonferroni correction method. Inter-rater reliability was
determined by comparing the number of studies searched
by Author 1 versus the number searched by Author 2 in
each stage of the search by the kappa coefficient [5].
All variables were tested for normality using the
Kolgomorov-Smirnov test. The parametric variables
were described as the means and standard deviations,
and the nonparametric variables were described as the
medians and interquartile ranges. All of the analyses
were made using Review Manager version 5.1 (Copenha-
gen: The Nordic Cochrane Center, The Cochrane Colla-
boration, 2011) and Statistical Package for the Social
Sciences version 16.0 (SPSS Inc., Chicago IL, USA). For
all analyses, P < 0.05 was considered significant. For
publication bias, P < 0.1 was considered significant.
Results
Literature search
The search strategy retrieved 105 unique citations. Of
these citations, 84 were excluded after the first screening
based on the abstracts or titles, leaving 21 articles for a
full-text review (Figure 1). In this review, 12 articles were
excluded for the following reasons: outcome of interest
not described (n = 5); study design not appropriate (n =
4); pediatric patients (n = 2); and evaluated vasopressin in
both arms (n = 1). Finally, nine articles (998 participants)
were included in the meta-analysis [6-14]. For all of the
comparisons of inter-rater reliability in each stage of the
search, the kappa coefficient ranged from 0.87 to 0.93.
Figure 1 Literature search strategy. AVP, vasopressin.
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Study characteristics
The characteristics of the nine selected studies are shown
in Table 1. Six studies evaluated vasopressin as a thera-
peutic approach, two evaluated terlipressin and one study
evaluated both. In seven studies the disease responsible
for vasodilatory shock was septic shock exclusively, in
one study the shock occurred after post-left ventricular
assist device, and in the last study the shock occurred
post cardiotomy. The mean dose of the drugs across the
studies was 38.72 ± 40.14 μg/minute for norepinephrine,
0.055 ± 0.027 U/minute for vasopressin, and 59.03 ±
47.59 μg/hour for terlipressin. The mean age was 61.91 ±
6.29 in entire group, and the median follow-up time was
24 (4.00 to 48.0) hours. The assessment of the study
quality is exposed in Table S1 in Additional file 2.
Vasopressin and terlipressin in vasodilatory shock:
hemodynamic and biochemical effects
Table S2 in Additional file 2 shows the changes in the
hemodynamic variables of the vasopressin, terlipressin,
and control patients in each study and in a combined
analysis. Compared with the control group, the vasopres-
sin group showed a significant reduction in heart rate
(-12.8 ± 6.14% vs. -1.62 ± 6.86%; P = 0.023), and a non-
significant increases in central venous pressure (+19.0 ±
1.41% vs. +10.66 ± 9.29%; P = 0.083), stroke volume
index (+14.0 ± 8.54% vs. +1.00 ± 2.94%; P = 0.05), and
left ventricular stroke work index (+65.00 ± 5.65% vs.
29.0 ± 26.54%; P = 0.064). When compared with terli-
pressin group, the vasopressin group showed a nonsigni-
ficant smaller reduction in cardiac index (-4.00 ± 9.25%
vs. -16.33 ± 4.04%; P = 0.070). Compared with the con-
trol group, the terlipressin group showed a significant
reduction in heart rate (-17.3 ± 7.09% vs. -1.62 ± 6.86%;
P = 0.011) and oxygen delivery index (-16.0 ± 2.64% vs.
-2.0 ± 6.28%; P = 0.036), and a borderline significant
reduction in the oxygen consumption index (-11.33 ±
6.02% vs. -1.00 ± 5.65%; P = 0.071).
Table S3 in Additional file 2 shows the changes in the
laboratorial variables of the vasopressin, terlipressin, and
control patients in each study and in the combined analy-
sis. There were no differences among the groups accord-
ing to the variables evaluated. In the analyses of the
standardized mean difference, we found a significant dif-
ference between the terlipressin and control groups in
the cardiac index (-0.44 (-0.87 to -0.02); P = 0.04) and
oxygen delivery index (-0.79 (-1.23 to -0.36); P = 0.0004),
and a tendency toward a reduction in the gastric PaCO2
gap difference (-0.47 (-0.96 to 0.01); P = 0.06) (Figures S1
to S5 in Additional file 3).
There was a significant reduction in the norepinephr-
ine requirement among the patients receiving either a
terlipressin or a vasopressin infusion. In the analyses of
the standardized mean difference, there is a significant
difference between the vasopressin and control patients
(-1.56 (-1.71 to -1.41); P < 0.0001) and between the
terlipressin and control patients (-1.97 (-2.62 to -1.32);
P < 0.0001) with respect to the norepinephrine dosages
(Figure 2).
Vasopressin and terlipressin in vasodilatory shock:
mortality and adverse events
The association of vasopressin with a decreased dose of
norepinephrine infusion reduced mortality in adult
patients (RR, 0.87 (0.76 to 1.00); P = 0.05). The terlipres-
sin infusion did not influence mortality (RR, 0.88 (0.62 to
1.25); P = 0.47), and in the combined analysis terlipressin
+ vasopressin resulted in a decreased mortality (RR, 0.87
(0.77 to 0.99); P = 0.04) (Figure 3). With respect to
adverse events, vasopressin and control patients were
analyzed because no study that evaluated the effects of
terlipressin described adverse events (see Table S4 in
Additional file 2). There was no difference in adverse
events between the vasopressin and control groups (RR,
0.98 (0.65 to 1.47); P = 0.92) (Figure S6 in Additional file
3). There is no correlation between the magnitude of the
reduction of norepinephrine during follow-up and the
risk ratio for mortality (r = 0.143; P = 0.652).
To explore the study heterogeneity, stratified analyses
were performed across a number of key study character-
istics and clinical factors. The summary of the analysis is
shown in Table 2, and the complete analysis is shown in
Table S5 in Additional file 2. In the survival analysis, we
found a reduction in mortality with vasopressin patients
with septic shock (P = 0.05) (Figure 3). The number
needed to treat for this condition was 1 to 15. This effect
on mortality disappeared after analysis without the study
by Russell and colleagues [10]. The reduction in norepi-
nephrine requirement was more significant in the dou-
ble-blinded studies, in patients with septic shock, and
with smaller doses of vasopressin and terlipressin. When
we analyzed the data without the study by Russell and
colleagues [10], the standardized mean difference found
was smaller but still significant (Table S5 in Additional
file 2).
When analyzing only the double-blinded studies and
the patients with septic shock, vasopressin and terlipres-
sin were associated with an increase in cardiac index
compared with norepinephrine alone. However, these
findings were more significant in the studies with a
shorter follow-up and a smaller number of patients.
Higher doses of terlipressin (>40 μg/hour) were asso-
ciated with decreases in cardiac index, oxygen delivery
index, oxygen consumption index, and gastric PaCO2 gap
difference. Further, higher doses of vasopressin (>0.05 U/
minute) were associated with an increased gastric PaCO2
gap difference. Finally, bolus infusion of terlipressin was
associated with a significant reduction of the oxygen
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Table 1 Characteristics of the studies included in the systematic review
Study Arms n Age (years) Design Disease Dosage Prognostic index Time (hours) MAP objective (mmHg)
Albanèse and colleagues [6] N 10 65 RCT Septic shock 119 μg/minute 29 (APACHE II) 6 65 ± 10
TP 10 66 OL 50 μg/hour 28 (APACHE II) 6
Dünser and colleagues [7] N 24 68 RCT Vasodilatory shock 58.8 μg/minute 49.7 (SAPS II) 48 >70
N+AV 24 68 OL (PS in 40%) 0.06 U/minute 51.6 (SAPS II) 48
Morelli and colleagues [8] N 15 64 RCT Septic shock 15 μg/minute 58 (SAPS II) 48 70 ± 5
N+TP 15 67 OL 110.5 μg/hour 62 (SAPS II) 48
N+AV 15 66 0.03 U/min 60 (SAPS II) 48
Morelli and colleagues [9] N 20 67 RCT Septic shock 84 μg/minute 59 (SAPS II) 4 70 ± 5
N+TP 19 66 OL (N >0.9 μg/kg/minute) 16.6 μg/hour 60 (SAPS II) 4
Russell and colleagues [10] N 382 62 RCT Septic shock 15 μg/minute 27.1 (APACHE II) 672 65 ± 10
N+AV 397 59 DB (N >5 μg/minute) 0.03 U/minute 27 (APACHE II) 672
Argenziano and colleagues [11] N+P 5 52 RCT Vasodilatory shock 19.7 μg/minute - 0.25 >70
N+AV 5 52 DB Post-LVAD 0.1 U/minute 0.25
Patel and colleagues [12] N 11 68 RCT Septic shock 17 μg/minute 24 (APACHE II) 4 Physician decision
N+AV 13 68 DB (high doses of D) 0.06 U/minute 22 (APACHE II) 4
Malay and colleagues [13] N+P 5 56 RCT Septic shock 12 μg/minute 26 (APACHE II) 24 >70
N+AV 5 53 DB 0.04 U/minute 27 (APACHE II) 24
Lauzier and colleagues [14] N 10 58 RCT OL Septic shock 28.1 μg/minute 23.5 (APACHE II) 48 >70
N+AV 13 51 (<12 hours of shock) 0.09 U/minute 22. (APACHE II) 48
Total C 482 62.23 ± 5.70 - - 38.72 ± 40.14 - 24 (4 to 48)
AV 472 59.60 ± 7.68 0.05 ± 0.02 36 (24 to 48) -
TP 44 66.33 ± 0.57 59.03 ± 47.59 6 (4 to 48)
Data presented as mean ± standard deviation or median (interquartile range). AV, arginine vasopressin; C, control; D, drug that the patients were already receiving at baseline; DB, double-blind; LVAD, left ventricular














delivery index and a borderline significant reduction
of the cardiac index. These findings were not found
with the continuous infusion. The Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) evidence profile for the impact of vasopressin
for the treatment of vasodilatory shock from this sys-
tematic review and meta-analysis of randomized con-
trolled trials is shown in Table S6 in Additional file 2.
Figure 2 Standardized mean difference for norepinephrine reduction between vasopressin/terlipressin and control. Vasopressin (AVP)
and terlipressin (TP) was associated with a significantly standardized mean difference with control (P < 0.0001 for both comparisons). CI,
confidence interval; SD, standard deviation.
Figure 3 Meta-analysis of overall survival for vasopressin, norepinephrine and terlipressin combined analyses. Meta-analysis of overall
survival for vasopressin (AVP) + norepinephrine (NE) or terlipressin (TP) + NE in vasodilatory shock, and for AVP + NE in septic shock. CI,
confidence interval; M-H, Mantel and Haenszel.
Serpa Neto et al. Critical Care 2012, 16:R154
http://ccforum.com/content/16/4/R154
Page 6 of 10
Table 2 Summary of stratified analyses of pooled relative risks and standardized mean difference
Stratified analysis Trials n Vasopressin P value Heterogeneity Terlipressin P value Heterogeneity
Mortality
Disease
Septic shock 4 989 0.87 (0.75 to 1.00) 0.05 0.76 0.88 (0.62 to 1.25) 0.47 0.61
Nonseptic shock 2 58 0.95 (0.65 to 1.37) 0.77 0.46 - - -
Norepinephrine reduction
Design
Double-blind 3 813 -1.75 (-1.91 to -1.59) <0.0001 <0.0001 - - -
Open-label 5 170 -0.45 (-0.85 to -0.06) 0.03 0.70 -1.97 (-2.62 to -1.32) <0.0001 <0.0001
Disease
Septic shock 6 925 -1.64 (-1.79 to -1.48) <0.0001 <0.0001 -1.97 (-2.62 to -1.32) <0.0001 <0.0001
Nonseptic shock 2 48 -0.66 (-1.22 to -0.11) 0.02 0.03 - - -
Vasopressin dosage
≤0.05 U/minute 2 809 -1.66 (-1.83 to -1.50) <0.0001 0.005 - - -
>0.05 U/minute 4 105 -0.77 (-1.22 to -0.32) 0.0008 <0.0001 - - -
Terlipressin dosage
≤40 μg/hour 1 39 - - - -4.63 (-5.88 to -3.38) <0.0001 -
>40 μg/hour 1 30 - - - -0.98 (-1.74 to -0.22) 0.01 -
Cardiac index
Design
Double-blind 3 46 0.94 (0.29 to 1.58) 0.004 0.45 - - -
Open-label 6 190 0.03 (-0.36 to 0.42) 0.89 0.80 -0.44 (-0.87 to -0.02) 0.04 0.54
Disease
Septic shock 7 176 0.44 (-0.00 to 0.88) 0.05 0.10 -0.44 (-0.87 to -0.02) 0.04 0.54
Nonseptic shock 2 58 0.05 (-0.47 to 0.56) 0.86 0.70 - - -
Terlipressin dosage
≤40 μg/hour 1 39 - - - -0.29 (-0.92 to 0.35) 0.38 -
>40 μg/hour 2 50 - - - -0.57 (-1.14 to -0.00) 0.05 0.37
Follow-up
≤24 hours 5 103 0.94 (0.29 to 1.58) 0.004 0.45 -0.48 (-1.00 to 0.04) 0.07 0.28
>24 hours 4 131 0.03 (-0.36 to 0.42) 0.89 0.80 -0.37 (-1.09 to 0.35) 0.31 -
Patients
≤25 5 87 0.52 (0.02 to 1.03) 0.04 0.12 -0.91 (-1.84 to 0.02) 0.06 -
25 to 50 4 147 0.08 (-0.36 to 0.53) 0.72 0.65 -0.32 (-0.80 to 0.15) 0.18 0.86
Oxygen delivery
Terlipressin dosage
≤40 μg/hour 1 39 - - - -0.75 (-1.40 to -0.10) 0.02 -
>40 μg/hour 2 50 - - - -0.83 (-1.42 to -0.25) 0.005 0.38
Oxygen consumption
Terlipressin dosage
≤40 μg/hour 1 39 - - - -0.13 (-0.76 to 0.50) 0.69 -
>40 μg/hour 2 50 - - - -0.52 (-1.08 to 0.05) 0.07 0.64
Gastric PaCO2 gap
Vasopressin dosage
≤0.05 U/minute 1 30 -0.38 (-1.11 to 0.34) 0.30 - - - -
>0.05 U/minute 3 95 0.43 (0.01 to 0.84) 0.04 0.09 - - -
Terlipressin dosage
≤40 μg/hour 1 39 - - - -0.15 (-0.78 to 0.48) 0.64 -
>40 μg/hour 1 30 - - - -0.94 (-1.70 to -0.18) 0.02 -
Data presented as relative risks (95% confidence interval) for mortality; and as the standardized mean difference (95% confidence interval for cardiac index,
norepinephrine reduction, oxygen delivery, oxygen consumption, and gastric PaCO2 gap.
Serpa Neto et al. Critical Care 2012, 16:R154
http://ccforum.com/content/16/4/R154
Page 7 of 10
Discussion
This systematic review suggests that the combination of
vasopressin with norepinephrine in vasodilatory shock is
safe, is associated with a reduction in patient mortality,
and facilitates weaning of catecholamines, avoiding the
latter’s potential adverse events. Vasopressin and terli-
pressin did not decrease the cardiac or oxygen delivery
indices. All of these changes are more significant in
patients with septic shock. The stratified analysis of
vasopressin combined with norepinephrine in patients
with septic shock was associated with a borderline sig-
nificant increase in hospital survival when compared
with norepinephrine alone.
Vasodilatory shock pathogenesis is multifactorial.
Increased nitric oxide, consequent to the activation of
inducible nitric oxide synthase, is a major contributor to
vasodilatation, acting both directly and via cyclic guano-
sine monophosphate to lower intracellular calcium levels,
to decrease myosin light chain phosphorylation, and to
activate calcium-sensitive (KCa) and adenosine tripho-
sphate-sensitive (KATP) K
+ channels [1,15]. An increasing
number of studies have consistently found that patients
who have vasodilatory shock and are evaluated in the
ICU setting have very low plasma levels of vasopressin
[16]. Hence, a relative deficiency of vasopressin may also
be crucial to the altered functional status of vascular
smooth muscle.
The clinical use of vasopressin has followed observations
suggesting that exogenous administration of vasopressin
during shock increases systemic blood pressure [17].
Blood pressure restoration does not necessarily improve
outcome, however, if the increased blood pressure is
accompanied by a worsening of cardiac performance and
by decreased cardiac output and oxygen delivery [18,19].
High doses of vasopressin are associated with decreased
cardiac output, oxygen delivery and consumption, and
with increased gastric PaCO2 gap difference [20]. High-
dose vasopressin is thus not indicated as an alternative to
other vasopressors for the treatment of vasodilatory shock.
One important limitation to address is that the effects
detected by our paper might be related to the decreasing
doses of catecholamines instead of the fixed dose of addi-
tional vasopressor (although we did not find a relation-
ship between reduction of norepinephrine and mortality).
There is a current trend for decatecholaminization of
patients, because catecholamines have deleterious effects
on immune function, thrombogenicity and metabolic
efficiency, on stimulating bacterial growth, and on caus-
ing myocardial injury [21]. In fact, higher mortality was
noted in those patients where higher mean blood pres-
sure values were generated using a progressively higher
catecholamine dose [21].
We also found that vasopressin significantly reduced
the heart rate in patients with vasodilatory shock
without changes in cardiac output. This is an important
finding because it could prevent the development and/
or progression of the myocardial dysfunction associated
with septic shock and the tachycardia-induced cardio-
myopathy [22]. Recent studies also suggest that diastolic
dysfunction is a common finding in patients with septic
shock and is a major predictor of mortality in these
patients [23]. As we already know, reducing the heart
rate in patients with diastolic dysfunction can achieve
adequate ventricular filling.
We found differences between the regimen used for
administration of terlipressin (bolus versus continuous).
Previous studies have suggested that intermittent bolus
injection may be associated with significant adverse effects,
including excessive microregional and systemic vasocon-
striction, as well as decreases in cardiac output and oxygen
delivery [24]. Conversely, recent studies provide evidence
that continuous infusion of low-dose terlipressin exerts
beneficial hemodynamic effects with reduced side effects
as compared with traditional bolus injection. In general,
continuous low-dose terlipressin was associated with
improved parameters of myocardial contractility and renal
function as well as less vascular leakage compared with
bolus injection [24].
The largest randomized controlled trial of vasopressin
infusion in septic shock showed no benefit of vasopressin
versus norepinephrine [10]. However, this study has
some interesting points to be discussed. First, it was
found in the vasopressin-treated patients with less severe
shock that the 25.8% relative reduction in 28-day mortal-
ity compared with norepinephrine was both striking and
significant. This result is consistent with the evidence of
a better synergistic effect of low-dose vasopressin in
isolated arteries with conditions mimicking less severe
septic shock [25]. Secondly, the dose of vasopressin cho-
sen is lower than that generally used. Thirdly, the mortal-
ity in the control group is lower than the 60% anticipated
in the sample size calculation, which could make the
study underpowered to detect a significant difference in
the outcome. Finally, the mean norepinephrine dose at
randomization was considered too low by some studies
[26]. However, in our stratified analysis no relationship
between the baseline dose of norepinephrine and out-
come was found (data not shown).
Polito and colleagues recently published a meta-analy-
sis of vasopressin in vasodilatory shock with important
differences from our study [27]. First, we analyzed only
adult patients because pediatric shock has a much lower
mortality than adult shock and this may contaminate the
overall results. Also, we performed a more robust electro-
nic search of references that resulted in the addiction of
one study [11] that was missed by Polito and colleagues.
Finally, we evaluated a higher number of variables, con-
ducted an analysis based on the standardized mean
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difference of reduction in norepinephrine requirement,
and performed a more robust sensitivity analysis.
These reported findings should be viewed within the
context of the limitations of this study and research in
the field. Although our literature search procedures
were extensive, other trials may have appeared or may
not have been published, and publication bias is there-
fore possible, which could overestimate the efficacy of
these treatments. The assessment of adverse effects was
limited to those studies in which adverse events were
explicitly reported. The changes in hemodynamic and
biochemical variables were calculated, and the standard
deviations were probably biased because the correlation
within patients is not reported. In addition, another lim-
itation of our meta-analysis is that it is dominated by
the largest randomized controlled trial from Russell and
colleagues [10]. Finally, assumptions used to calculate
the drug dosage may have influenced the results.
Conclusions
The present meta-analysis has demonstrated the benefit
of the association of vasopressin and terlipressin in
reducing norepinephrine requirements in patients with
vasodilatory shock, particularly in patients with septic
shock. Our results show that vasopressin treatment is
not associated with decreased cardiac output or oxygen
delivery and consumption, even in higher doses. How-
ever, the pooled analyses showed that higher doses of
terlipressin were associated with worsening of these
variables. Vasopressin significantly reduces mortality in
general patients, and specifically in patients with septic
shock.
Key messages
• Vasopressin and terlipressin reduce the norepinephr-
ine requirements in patients with vasodilatory shock.
• Vasopressin is not associated with decreased cardiac
output or oxygen delivery and consumption.
• Vasopressin significantly reduces mortality in
patients with septic shock.
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